-
Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care
•
Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached DKK 290.403 billion (USD 42.1 billion), marking a 26% year-on-year (YOY) increase at constant exchange rates (CER). The strong performance was driven by growth across all business sectors, with notable increases in GLP-1 diabetes, Insulin,…
-
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
•
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis’ TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary…
-
Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH
•
Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of the Phase III ESSENCE study, a pivotal 240-week, double-blinded trial involving 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, has successfully reached its primary endpoints. The trial evaluated the efficacy…
-
Novo Nordisk Faces US Senators’ Scrutiny Over Levemir Withdrawal
•
US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo Nordisk’s (NYSE: NVO; CPH: NOVO-B) decision to discontinue the sales of its long-acting insulin brand Levemir (insulin detemir) in the US market. The company announced in November 2023 its intention to cease distribution by the…
-
Novo Nordisk Partners with Indonesia’s Bio Farma to Boost Asia-Pacific Diabetes Drug Production
•
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia’s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding,…
-
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
•
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious market launch for the anti-obesity drug Wegovy (semaglutide) in China following its recent approval. The strategy is aimed at preserving manufacturing capacity and maintaining the stability of global supply chains, according to Maziar Mike Doustdar,…
-
Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial
•
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline candidate ocedurenone has failed in a Phase III trial for chronic kidney disease (CKD). The drug did not meet the primary endpoint in the CLARION-CKD study, leading to the cancellation of its development for CKD.…
-
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
•
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for semaglutide, indicated for long-term weight management. Globally, Novo Nordisk markets semaglutide under the trade name Wegovy for weight loss. The STEP series…
-
Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support
•
Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase a majority stake in Austria-based Single Use Support, a company that supplies equipment and consumables to the biopharmaceutical industry. The financial details of the transaction were not disclosed. As stated in the press release, Single…
-
Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials
•
At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B) presented findings from two studies on its weight loss therapy Wegovy (semaglutide). The data indicated that Wegovy’s weight loss effects can be sustained for up to 4 years, along with cardiovascular benefits, irrespective of the…
-
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
•
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific antibody (BsAb) Mim8 has successfully met the primary endpoints in a late-stage trial for haemophilia A. The trial focused on the reduction of treated bleeding episodes, with once-weekly and once-monthly doses of Mim8 showing reductions…
-
Novo Nordisk’s Mim8 for Haemophilia A Exceeds Endpoints in Late-Stage Trial
•
Denmark-based healthcare company Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial of its bispecific antibody (BsAb) Mim8, used for the treatment of haemophilia A. The trial successfully met its primary endpoints, which focused on the reduction of treated bleeding episodes. The study demonstrated that once-weekly and…
-
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
•
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in global sales for the first quarter of 2024, reaching DKK 65.3 billion (USD 9.4 billion) at constant exchange rates (CER). The growth was primarily attributed to strong performances in glucagon-like peptide-1 (GLP-1)-based drugs and obesity…
-
Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio
•
Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a leading expert in RNA biology focused on the prevention, repair, and reversal of cardiovascular diseases (CVDs). The deal, valued at EUR 1.025 billion, which includes upfront and milestone payments, is anticipated to finalize in the…
-
Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe
•
Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with U.S. raw materials supplier Actylis. The agreement facilitates the distribution of Novo’s benzalkonium chloride (BKC) in Germany, Ireland, Spain, Portugal, and the UK, expanding upon an existing deal for North American markets. Benzalkonium chloride is…
-
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
•
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide) take the lead in total US prescriptions over its competitor Eli Lilly’s (NYSE: LLY) Zepbound (tirzepatide), according to Reuters. Despite this, Zepbound has seen more new prescriptions filled, indicating a close competition in a market…
-
Novo Nordisk Partners with Neomorph to Target Undruggable Diseases with Molecular Glue Degraders
•
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has entered into a partnership with US-based Neomorph to discover, develop, and commercialize molecular glue degraders targeting specific indications in cardiometabolic and rare diseases. Neomorph will be responsible for the discovery and pre-clinical development of the candidates, for which it will receive up…
-
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
•
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive agreement to acquire contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) for $16.5 billion. The transaction is expected to be finalized by the end of the year, pending customary regulatory conditions. This acquisition comes…
-
Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management
•
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial of its antidiabetic combination therapy, IcoSema (insulin icodec + semaglutide), in patients with type 2 diabetes (T2D) inadequately controlled on daily basal insulin. In comparison to insulin glargine plus insulin aspart, once-weekly IcoSema demonstrated non-inferiority,…
